Danaher/$DHR
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Danaher
In 1984, Danaher's founders transformed a real estate organization into an industrial-focused manufacturing company. Then, through a series of mergers, acquisitions, and divestitures, Danaher now focuses primarily on manufacturing scientific instruments and consumables in the life sciences and diagnostic industries after the late 2023 divestiture of its environmental and applied solutions group, Veralto.
- Ticker
- $DHR
- Sector
- Health
- Primary listing
- NYSE
- Employees
- 59,000
- Headquarters
- Washington, United States
- Website
- www.danaher.com
Danaher Metrics
BasicAdvanced
$166B
38.68
$6.10
0.80
$1.52
0.68%
Price and volume
Market cap
$166B
Beta
0.8
52-week high
$242.80
52-week low
$160.93
Average daily volume
4.3M
Dividend rate
$1.52
Financial strength
Current ratio
1.634
Quick ratio
1.194
Long term debt to equity
0.479
Total debt to equity
0.518
Dividend payout ratio (TTM)
23.46%
Interest coverage (TTM)
15.63%
Profitability
EBITDA (TTM)
8,256
Gross margin (TTM)
59.36%
Net profit margin (TTM)
16.91%
Operating margin (TTM)
21.97%
Effective tax rate (TTM)
10.98%
Revenue per employee (TTM)
$430,000
Management effectiveness
Return on assets (TTM)
4.06%
Return on equity (TTM)
8.19%
Valuation
Price to earnings (TTM)
38.683
Price to revenue (TTM)
6.51
Price to book
3.1
Price to tangible book (TTM)
-11.26
Price to free cash flow (TTM)
29.111
Free cash flow yield (TTM)
3.44%
Free cash flow per share (TTM)
8.111
Dividend yield (TTM)
0.64%
Forward dividend yield
0.68%
Growth
Revenue change (TTM)
5.52%
Earnings per share change (TTM)
25.42%
3-year revenue growth (CAGR)
6.79%
10-year revenue growth (CAGR)
4.42%
3-year earnings per share growth (CAGR)
-8.35%
10-year earnings per share growth (CAGR)
5.50%
3-year dividend per share growth (CAGR)
12.77%
10-year dividend per share growth (CAGR)
10.11%
What the Analysts think about Danaher
Analyst ratings (Buy, Hold, Sell) for Danaher stock.
Analyst projections of the future price of Danaher stock.
Bulls say / Bears say
Underlying growth excluding respiratory testing accelerated to 5.5% in the third quarter, and Danaher raised its 2026 adjusted EPS outlook to $8.57–$8.62. That points to improving demand translating into stronger earnings. (Danaher)
Bioprocessing revenue grew at the upper end of the mid-single-digit range, while orders rose by the mid-teens, led by upstream consumables and resins. Management expects bioprocessing growth to improve further in 2027. (The Motley Fool)
Respiratory testing remains a sizeable drag: Danaher expects it to cut fourth-quarter core growth by about 1.5 percentage points, leaving total core growth at around 3%. Continued weakness in this business could keep reported growth subdued. (Danaher)
Demand remains uneven across customer groups: developed-market revenue was flat, academic demand was still below historic levels, and Discovery and Medical revenue declined by low single digits. That weak patch may limit how quickly the recovery spreads across Danaher’s businesses. (The Motley Fool)
Bioprocessing shipments have proved vulnerable to customer timing changes: Danaher’s second-quarter results included weaker-than-expected biotechnology revenue after customers delayed large resin purchases. Even with stronger orders in the third quarter, converting those orders into revenue remains a risk. (Reuters, The Motley Fool)
Data summarised monthly by Lightyear AI. Last updated on 9 Nov 2026.
Danaher Financial Performance
Revenues and expenses
Danaher Earnings Performance
Company profitability
Upcoming events
No upcoming events
Danaher News
AllArticlesVideos
Funds containing Danaher
AllUSDEURGBP
Fund name | Fund size | $DHR weighting |
|---|---|---|
VanEck Morningstar Wide Moat€GMVM | $376M | 2.66% |
VanEck Morningstar Wide Moat$MOAT | $396M | 2.66% |
VanEck Morningstar Wide Moat£MOGB | $376M | 2.66% |
Invesco Health Care S&P US Select Sector$XLVS | $552M | 2.30% |
Invesco Health Care S&P US Select Sector£XLVP | $552M | 2.30% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.